Tanshinone IIA combined with cisplatin synergistically inhibits non‐small‐cell lung cancer in vitro and in vivo via down‐regulating the phosphatidylinositol 3‐kinase/Akt signalling pathway

Cisplatin represents one of the first‐line drugs used for non‐small‐cell lung cancer treatment. However, considerable side effects and the emergence of drug resistance are becoming critical limitations to its application. Combinatorial strategies may be able to extend the use of cisplatin. Both Tans...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Phytother Res
Autors principals: Liao, Xiao‐Zhong, Gao, Ying, Huang, Sheng, Chen, Zhuang‐Zhong, Sun, Ling‐Ling, Liu, Jia‐Hui, Chen, Han‐Rui, Yu, Ling, Zhang, Jia‐Xing, Lin, Li‐Zhu
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6772065/
https://ncbi.nlm.nih.gov/pubmed/31268205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ptr.6392
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars